10% Aminolevulinic Acid Photodynamic Therapy Using Broadband Light for the Treatment of Facial Actinic Keratoses and Photodamage: A Proof-of-Concept Study
SKIN The Journal of Cutaneous Medicine · 10.11.2026 · 10 (6) · s826
DOI: 10.25251/eytnnj36 ↗Kurz gefasst
Fachartikel in der Zeitschrift SKIN The Journal of Cutaneous Medicine, online erschienen am 10.11.2026. Verfasst von Sherrif Ibrahim. Die Arbeit nennt 2 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Photodynamic therapy (PDT) with topical aminolevulinic acid (ALA) is an established field-directed treatment for actinic keratoses (AK). Conventional activation uses narrowband red light near 635 nm, engaging a single absorption peak of protoporphyrin IX (PpIX). PpIX also absorbs at bands near 505, 540, and 580 nm. A broadband visible source spanning 500-650 nm could therefore engage several Q-bands simultaneously, while a sequential longer-wavelength pass may extend effect to deeper targets. We evaluated the feasibility, tolerability, and objective cutaneous effects of activating 10% ALA gel with sequential dual-filter broadband light.
Methods
Single-center, open-label, single-arm investigator-initiated study of 10 adults with facial AK and visible hallmarks of photodamage. 10% ALA gel (Ameluz, Biofrontera, Inc) was applied to the full face with a 60-minute incubation. Numbing before illumination was offered as an option. Illumination used two sequential broadband light (Sciton Inc, Palo Alto, CA) passes: a 500-650 nm filter at 3 J/cm2, 3 ms for 10-12 passes, followed by a 640-1400 nm filter at 3 J/cm2, 3 ms 10-12 passes. Two treatments were performed approximately one month apart. Standardized multimodal facial imaging was obtained at baseline, at the second treatment, and one and two months thereafter. Formal lesion counts were not performed, as confluent field involvement precluded meaningful enumeration. Pain during illumination, adverse events, downtime, and patient satisfaction were recorded.
Results
Serial standardized photography demonstrated visible reduction in erythema, scale, and extent of involvement within the treated field; representative cases are presented. On multimodal imaging one month after the second treatment, vascular (red area) features decreased by a mean of 22%, improving in 9 of 10 subjects (p=0.004); pore counts decreased 11% (p=0.03). Pain during illumination was rated as “none” to “mild” in 10 of 10 subjects. Adverse events were limited to transient erythema and mild edema; All 10 subjects reported satisfaction with the outcome and 9 of 10 would elect repeat treatment.
Conclusions
In this small uncontrolled study, broadband light activation of 10% ALA gel was feasible and well tolerated, with photographic improvement in the treated field and measurable change in objective vascular and textural parameters. Overlap of the 500-650 nm filter with several PpIX Q-bands provides a mechanistic rationale for activation by this source and provides a dual benefit of reduction in AK as well as skin rejuvenation in a well-tolerated, effective delivery approach. Interpretation is limited by small sample size, absence of a comparator arm, absence of formal lesion counts, and the fact that multimodal imaging does not directly quantify AK.Support: ALA gel for this study was provided by Biofrontera Inc.
Zitieren
APA
Ibrahim, S. (2026). 10% Aminolevulinic Acid Photodynamic Therapy Using Broadband Light for the Treatment of Facial Actinic Keratoses and Photodamage: A Proof-of-Concept Study. SKIN The Journal of Cutaneous Medicine, 10(6), s826. https://doi.org/10.25251/eytnnj36
Vancouver
Ibrahim S. 10% Aminolevulinic Acid Photodynamic Therapy Using Broadband Light for the Treatment of Facial Actinic Keratoses and Photodamage: A Proof-of-Concept Study. SKIN The Journal of Cutaneous Medicine. 2026;10(6):s826. doi:10.25251/eytnnj36
BibTeX
@article{Ibrahim2026,
author = {Ibrahim, Sherrif},
title = {10% Aminolevulinic Acid Photodynamic Therapy Using Broadband Light for the Treatment of Facial Actinic Keratoses and Photodamage: A Proof-of-Concept Study},
journal = {SKIN The Journal of Cutaneous Medicine},
year = {2026},
volume = {10},
number = {6},
pages = {s826},
doi = {10.25251/eytnnj36}
}
EUVIMED